ArticleInternational journal of clinical oncology2026
Breast cancer burden among women of reproductive age in China, Japan, and South Korea, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Estrogen metabolites in premenopausal women living in China, Mongolia, and the United Kingdom.BMC cancer · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is the most common cancer among women globally, with incidence rates rising annually. However, systematic comparative studies on the burden of breast cancer among women of reproductive age in East Asian countries are currently lacking.
methodsThis study utilized the Global Burden of Disease (GBD) 2021 database to extract incidence, prevalence, mortality, disability-adjusted life years (DALYs) for breast cancer among women of reproductive age in China, Japan, and South Korea. Cross-national comparisons were conducted using age-standardized rates (ASR), and estimated annual percentage change (EAPC) and average annual percentage change (AAPC) were calculated. Joinpoint regression analysis identified trend turning points, and ARIMA models projected trends for 2022-2036.
resultsFrom 1990 to 2021, China, Japan, and South Korea exhibited upward trends in age-standardized incidence rates (ASIR) and age-standardized prevalence rates (ASPR) for breast cancer (ASIR: China's EAPC = 2.17, Japan's EAPC = 0.93, South Korea's EAPC = 3.86). Age-standardized mortality rates (ASMR) and age-standardized DALYs rates (ASDR) generally declined in China and Japan but increased in South Korea (ASMR: China's EAPC = -1.10, Japan's EAPC = -0.64, South Korea's EAPC = 0.11). Projections for the next 15 years indicate rising ASIR and ASPR in China, declining trends in Japan, and stabilization in South Korea; overall declines in ASMR and ASDR across all three countries.
conclusionThe findings emphasize the importance of enhanced, country-specific screening and prevention efforts for breast cancer among reproductive-age women in East Asia to address disparities in disease burden and early detection.
Indexed as
Identifiers
41718840What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.